Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
This infographic focuses on clinician perceptions of adverse events associated with the use of olanzapine and how they rated proposed strategies to help maintain therapy when it is otherwise effective. It covers clinician-ranked options such...
This infographic focuses on clinician perceptions of adverse events associated with the use of olanzapine and how they rated proposed strategies to help maintain therapy when it is otherwise effective. It covers clinician-ranked options such...
This video focuses on clinician perceptions of adverse events associated with the use of olanzapine and how they rated proposed strategies to help maintain therapy when it is otherwise effective. It covers clinician-ranked options such as...
This video focuses on clinician perceptions of adverse events associated with the use of olanzapine and how they rated proposed strategies to help maintain therapy when it is otherwise effective. It covers clinician-ranked options such as...
This infographic reviews clinician perceptions of where a commonly used second-generation antipsychotic performs best. It also outlines common clinical scenarios in which respondents report preferring this option, translating perceptions into...
This infographic reviews clinician perceptions of where a commonly used second-generation antipsychotic performs best. It also outlines common clinical scenarios in which respondents report preferring this option, translating perceptions into...
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
